Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma

References

• Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. ERS/ATS Statement: Management of malignant pleural effusion. Eur Respir J 2001; 18:402 - 19; http://dx.doi.org/10.1183/09031936.01.00225601; PMID: 11529302
   PubMed Web of Science ®Google Scholar
• Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008; 83:235 - 50; PMID: 18241636
   PubMed Web of Science ®Google Scholar
• Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65:Suppl 2 ii32 - 40; http://dx.doi.org/10.1136/thx.2010.136994; PMID: 20696691
   PubMed Web of Science ®Google Scholar
• Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr., et al, International Association for the Study of Lung Cancer International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2:686 - 93; http://dx.doi.org/10.1097/JTO.0b013e31811f4703; PMID: 17762334
   PubMed Web of Science ®Google Scholar
• Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008; 19:334 - 9; http://dx.doi.org/10.1016/j.ejim.2007.09.014; PMID: 18549935
   PubMed Web of Science ®Google Scholar
• Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest 2003; 123:1887 - 94; http://dx.doi.org/10.1378/chest.123.6.1887; PMID: 12796164
   PubMed Web of Science ®Google Scholar
• Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010; 21:30 - 4; http://dx.doi.org/10.1016/j.ejim.2009.09.012; PMID: 20122610
   PubMed Web of Science ®Google Scholar
• Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117:73 - 8; http://dx.doi.org/10.1378/chest.117.1.73; PMID: 10631202
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148 - 59; http://dx.doi.org/10.1056/NEJMra072067; PMID: 18337604
   PubMed Web of Science ®Google Scholar
• Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81:303 - 11; http://dx.doi.org/10.1111/j.1399-0004.2011.01809.x; PMID: 22082348
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303:21 - 8; http://dx.doi.org/10.1016/j.canlet.2010.12.011; PMID: 21255913
   PubMed Web of Science ®Google Scholar
• Ibáñez de Cáceres I, Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin Transl Oncol 2007; 9:429 - 37; http://dx.doi.org/10.1007/s12094-007-0081-9; PMID: 17652056
   PubMed Web of Science ®Google Scholar
• Benlloch S, Galbis-Caravajal JM, Martín C, Sanchez-Paya J, Rodríguez-Paniagua JM, Romero S, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006; 107:1859 - 65; http://dx.doi.org/10.1002/cncr.22190; PMID: 16983705
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Yung R, Guo M, Han Y, Ames SE, et al. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?. Ann Thorac Surg 2005; 80:1241 - 7; http://dx.doi.org/10.1016/j.athoracsur.2005.05.088; PMID: 16181847
   PubMed Web of Science ®Google Scholar
• Chen ML, Chang JH, Yeh KT, Chang YS, Chang JG. Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid. Kaohsiung J Med Sci 2007; 23:498 - 503; http://dx.doi.org/10.1016/S1607-551X(08)70007-X; PMID: 18055295
   PubMed Web of Science ®Google Scholar
• Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 2007; 120:2191 - 5; http://dx.doi.org/10.1002/ijc.22576; PMID: 17285579
   PubMed Web of Science ®Google Scholar
• Katayama H, Hiraki A, Fujiwara K, Matsuo K, Maeda T, Chikamori K, et al. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Asian Pac J Cancer Prev 2007; 8:221 - 4; PMID: 17696735
   PubMed Web of Science ®Google Scholar
• Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948; 1:634 - 56; http://dx.doi.org/10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373 - 83; http://dx.doi.org/10.1016/0021-9681(87)90171-8; PMID: 3558716
   PubMedGoogle Scholar
• Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006; 12:7329 - 38; http://dx.doi.org/10.1158/1078-0432.CCR-06-0894; PMID: 17189404
   PubMed Web of Science ®Google Scholar
• Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?. Ann Thorac Surg 2005; 79:1180 - 8, discussion 1180-8; http://dx.doi.org/10.1016/j.athoracsur.2004.09.060; PMID: 15797047
   PubMed Web of Science ®Google Scholar
• Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2005; 130:1378 - 84; http://dx.doi.org/10.1016/j.jtcvs.2005.06.015; PMID: 16256792
   PubMed Web of Science ®Google Scholar
• Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005; 11:4400 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-04-2378; PMID: 15958624
   PubMed Web of Science ®Google Scholar
• Hayashi H, Yazawa T, Okudela K, Nagai J, Ito T, Kanisawa M, et al. Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 2002; 93:184 - 9; http://dx.doi.org/10.1111/j.1349-7006.2002.tb01257.x; PMID: 11856482
   PubMedGoogle Scholar
• Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004; 202:215 - 23; http://dx.doi.org/10.1002/path.1507; PMID: 14743504
   PubMed Web of Science ®Google Scholar
• Bell CG, Beck S. The epigenomic interface between genome and environment in common complex diseases. Brief Funct Genomics 2010; 9:477 - 85; http://dx.doi.org/10.1093/bfgp/elq026; PMID: 21062751
   PubMed Web of Science ®Google Scholar
• Herceg Z, Vaissière T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 2011; 6:804 - 19; http://dx.doi.org/10.4161/epi.6.7.16262; PMID: 21758002
   PubMed Web of Science ®Google Scholar